Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B.

Autor:	Ubals M; Department of Dermatology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.; Doctoral Programme in Medicine and Translational Research: International Health Track, Facultat de Medicina, Universitat de Barcelona, 08036 Barcelona, Spain., Bosch-Nicolau P; Department of Infectious Diseases, Hospital Universitari Vall d'Hebron, PROSICS Barcelona, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain., Sánchez-Montalvá A; Department of Infectious Diseases, Hospital Universitari Vall d'Hebron, PROSICS Barcelona, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain., Salvador F; Department of Infectious Diseases, Hospital Universitari Vall d'Hebron, PROSICS Barcelona, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain., Aparicio-Español G; Department of Dermatology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.; Facultat de Medicina, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain., Sulleiro E; Department of Clinical Microbiology, Hospital Universitari Vall d'Hebron, PROSICS Barcelona, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain., Silgado A; Department of Clinical Microbiology, Hospital Universitari Vall d'Hebron, PROSICS Barcelona, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain., Soriano-Arandes A; Department of Paediatrics, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain., Espiau M; Department of Paediatrics, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain., Ferrer B; Department of Pathology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain., Pou D; Tropical Medicine and International Health Unit, Drassanes-Vall d'Hebron, PROSICS Barcelona, 08035 Barcelona, Spain., Treviño B; Tropical Medicine and International Health Unit, Drassanes-Vall d'Hebron, PROSICS Barcelona, 08035 Barcelona, Spain., Molina I; Department of Infectious Diseases, Hospital Universitari Vall d'Hebron, PROSICS Barcelona, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain., García-Patos V; Department of Dermatology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.; Facultat de Medicina, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Jazyk:	angličtina
Zdroj:	Pathogens (Basel, Switzerland) [Pathogens] 2021 Sep 28; Vol. 10 (10). Date of Electronic Publication: 2021 Sep 28.
DOI:	10.3390/pathogens10101253
Abstrakt:	Background: There is no consensus for the best treatment of complex cutaneous leishmaniasis (CL). We aimed to describe a cohort of CL, focusing on liposomal amphotericin B (L-AmB) treatment outcome. Methods: We performed a retrospective study in Vall d'Hebron University Hospital (Barcelona, Spain). All patients with parasitologically proven CL diagnosed from 2012 to 2018 were included. Results: The analysis included 41 patients with CL. The median age was 39 years (IQR 12- 66); 12 (29%) were children, and 29 (71%) were men. Regarding treatment, 24 (59%) received local treatment, whereas 17 (41%) had complex CL and were offered intravenous systemic treatment. Sixteen patients received L-AmB; eight (50%) had adverse events, and three (19%) discontinued treatment for safety reasons. All cases were considered cured within the first year post-treatment. Conclusions: L-AmB for complex CL showed no treatment failures, offering an alternative treatment option for patients with complex CL. Clinicians should pay close attention to the potential adverse events of L-AmB and adopt an active drug safety surveillance scheme to rapidly detect reversible side effects.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu